{"entity":{"id":"tumour-flare-on-bispecific-antibodies-and-immunomodulatory-drugs","kind":"protocol","name":"Tumour flare on bispecific antibodies and lenalidomide in lymphoma: recognition and management","aka":["tumour flare","tumor flare","tumour flare reaction","TFR","pseudoprogression in lymphoma","pseudo-progression","flare reaction on glofitamab","lenalidomide tumour flare","indeterminate response"],"tldr":"Some lymphoma medicines draw immune cells into the lymphoma, so lumps can swell and hurt for days or sometimes weeks. This is tumour flare, and it can look like the cancer growing when it is not. Painkillers and sometimes steroids are used. A lump near the windpipe or another vital organ can press on it, so tell your team straight away about swollen or sore lumps, chest pain or trouble breathing.","summary":"Tumour flare is a painful swelling of lymphoma sites, sometimes with new pleural effusions, low-grade fever or rash, in the first days to weeks of a T-cell-engaging bispecific antibody or of lenalidomide. The EU labels of all three bispecific antibodies say it is likely due to T cells moving into the tumour. It matters for two reasons: swelling next to an airway or vital organ can cause compression, and it can be mistaken for progression.\n\nRates and timing from the labels: glofitamab 12% (grade 3 in 2.8%), median onset 2 days after the first dose (range 1 to 16), median duration 3.5 days (range 1 to 35), almost all in cycle 1; mosunetuzumab 4% (US label) or 3.1% (EU label, median onset 13 days, median duration 36 days); epcoritamab 1.6% as monotherapy with a median onset of 19.5 days (EU label). On lenalidomide it was reported in 10% of patients in the mantle cell lymphoma trial (all grade 1 or 2, all in cycle 1), in 10.8% on lenalidomide with rituximab in the AUGMENT trial in follicular or marginal zone lymphoma (one grade 3), and in 4.1% in the MAGNIFY trial; one case in a separate mantle cell trial was fatal (US label). The US label says flare, including fatal reactions, occurred in investigational use for chronic lymphocytic leukaemia and lymphoma, and that lenalidomide is not indicated and not recommended for that leukaemia outside controlled trials.\n\nManagement is label-based. The US glofitamab and mosunetuzumab labels ask for close monitoring of people with bulky disease near an airway or vital organ during initial treatment, and all three EU labels ask for monitoring at critical anatomical sites; the US epcoritamab label gives no flare advice. The US glofitamab label withholds the drug for grade 2 to 4 flare and names an antihistamine and corticosteroids; the EU glofitamab label says corticosteroids and analgesics should be considered and has no hold rule for flare; the EU mosunetuzumab label withholds for grade 3 or 4 flare; the epcoritamab trial allowed treatment to continue through suspected flare. Lenalidomide may continue through grade 1 or 2 flare at the doctor's discretion, with NSAIDs, corticosteroids or opioid analgesics, and is withheld for grade 3 or 4 until it settles to grade 1 or less. A practice summary says flare can overlap with cytokine release syndrome and other toxicities, which are treated at the same time.\n\nThe LYRIC criteria, written for clinical trials, introduced an 'indeterminate response' category so that apparent progression on immune-modulating treatment is confirmed by biopsy or later imaging before it is called progression. No source read reports a trial comparing ways of managing flare. The reader's own team's protocol comes first.","asOf":"2026-11-17","links":[],"tags":[],"related":["bispecific-step-up-dosing","crs-grading-and-management","tumour-lysis-syndrome-prevention-and-treatment","svc-obstruction"],"cancers":["dlbcl","follicular-lymphoma","mantle-cell-lymphoma","marginal-zone-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["glofitamab","mosunetuzumab","epcoritamab","lenalidomide"],"companies":[],"institutions":[],"pathways":[],"terms":["crs","imid","lugano-classification","tumor-lysis-syndrome"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"simple":"In the first days or weeks of some lymphoma treatments, lumps can get bigger and sore for a while. This is called tumour flare and it does not mean the treatment has failed. If a lump swells or hurts, or you have chest pain or find it hard to breathe, tell your team straight away.","domain":"immunotherapy-toxicity","setting":{"who":["doctor","nurse","pharmacist","patient-or-carer"],"where":["chemotherapy-day-unit","ward","outpatient-clinic","home","telephone-triage","acute-oncology-service"]},"population":"Adults with B-cell non-Hodgkin lymphoma starting glofitamab, mosunetuzumab or epcoritamab, and adults with mantle cell, follicular or marginal zone lymphoma (or, in trials only, chronic lymphocytic leukaemia) starting lenalidomide. Lenalidomide for myeloma or myelodysplastic syndrome is not covered: the label describes tumour flare only in chronic lymphocytic leukaemia and lymphoma. Flare on checkpoint inhibitors, on bispecific antibodies for myeloma, and hormone flare in prostate or breast cancer are different problems and are not covered. Children are not covered.","trigger":"Before the first dose in anyone with bulky disease or disease next to an airway or vital organ, and whenever a lymphoma site swells or becomes painful, or breathlessness, chest pain, a new effusion, fever or rash appears in the first cycles.","steps":[{"action":"Before the first dose, note any bulky disease and any disease close to the airway or a vital organ, and plan closer monitoring for those patients during initial treatment","why":"The label warns that flare can cause compression or obstruction, where a swollen mass presses on what lies beside it.","source":"label-glofitamab","quote":"Patients with bulky tumors or disease located in close proximity to airways or a vital organ should be monitored closely during initial therapy."},{"action":"On lenalidomide, treat a high tumour burden as a risk for both tumour flare and tumour lysis, and monitor closely through the first cycle and any dose increase","why":"The EU label says the patients at risk of tumour flare and tumour lysis are those with a high tumour burden before treatment.","source":"smpc-revlimid","quote":"These patients should be monitored closely, especially during the first cycle or dose-escalation, and appropriate precautions taken."},{"action":"Keep lenalidomide for chronic lymphocytic leukaemia to controlled clinical trials: the US label says it is not indicated and not recommended outside them","why":"The US label reports more deaths on lenalidomide than on chlorambucil in a randomised trial in this leukaemia, and tumour flare reactions, some fatal, in investigational use for chronic lymphocytic leukaemia and lymphoma.","source":"label-lenalidomide","quote":"REVLIMID is not indicated and not recommended for use in CLL outside of controlled clinical trials."},{"action":"Tell the patient what flare feels like and to report it; the EU patient leaflets say to tell the doctor straight away","why":"The US label asks that patients report signs such as localised pain and swelling for evaluation. The EU glofitamab leaflet lists tender swollen lymph nodes, chest pain, difficulty breathing and pain at the tumour site among the serious side effects to report straight away.","source":"label-glofitamab","quote":"Inform patients of the potential risk of tumor flare reaction and to report any signs and symptoms associated with this event (e.g., localized pain and swelling) to their healthcare provider for evaluation"},{"action":"Recognise flare: new pain and swelling at known lymphoma sites, or breathlessness from a new pleural effusion; on lenalidomide, tender swollen nodes with low-grade fever, pain and rash","why":"These are the features the US glofitamab label and the US lenalidomide label describe.","source":"label-glofitamab","quote":"Manifestations include localized pain and swelling at the sites of the lymphoma lesions and/or dyspnea from new pleural effusions."},{"action":"Expect it early on glofitamab, within days of the first dose and mostly in cycle 1; the labels report later onset with mosunetuzumab and epcoritamab","why":"On glofitamab flare started a median of 2 days after the first dose (range 1 to 16) and lasted a median of 3.5 days (range 1 to 35). The EU labels give a median onset of 13 days for mosunetuzumab and 19.5 days for epcoritamab.","source":"label-glofitamab","quote":"Most tumor flare events occurred during Cycle 1, with a median time to first onset of 2 days (range: 1 to 16 days) after the first dose of COLUMVI."},{"action":"Do not record early swelling as treatment failure on its appearance alone: flare may mimic progression","why":"The EU glofitamab label and both lenalidomide labels say flare may mimic progression of disease. The LYRIC authors add that calling it progression could take people off a treatment they stand to benefit from.","source":"smpc-columvi","quote":"Tumour flare does not imply treatment failure or represent tumour progression."},{"action":"Where imaging suggests progression on an immune-modulating treatment despite evidence of clinical benefit, consider the LYRIC 'indeterminate response' category until a biopsy or later imaging shows flare or true progression","why":"LYRIC is a set of provisional recommendations written for clinical trials, and its abstract names checkpoint inhibitors rather than bispecific antibodies. Only the abstract could be read.","source":"lyric-2016","quote":"The term \"indeterminate response\" was introduced to identify such lesions until confirmed as flare/pseudo-progression or true PD by either biopsy or subsequent imaging."},{"action":"Look for cytokine release syndrome, neurotoxicity, tumour lysis and infection at the same time as flare, and treat what is found together","why":"A one-page practice summary says tumour flare, tumour lysis, low blood counts and immune compromise can have overlapping features with cytokine release syndrome and neurotoxicity, and that treatment should occur simultaneously.","source":"britto-2025","quote":"They can have overlapping clinical manifestations with CRS and ICANS, and treatment should occur simultaneously."},{"action":"Watch for signs that a swollen lymphoma site is compressing or obstructing an airway or organ and, if it is, start the standard treatment for that complication","why":"The US mosunetuzumab and glofitamab labels both ask for this monitoring. The EU labels describe a heightened risk of compromise and morbidity from mass effect where bulky tumours lie close to an airway or vital organ.","source":"label-mosunetuzumab","quote":"If compression or obstruction develops, institute standard treatment of these complications."},{"action":"For flare on a bispecific antibody, consider corticosteroids and analgesics (EU glofitamab label); the US glofitamab label names an antihistamine and corticosteroids as appropriate treatment for grade 2 to 4 flare","why":"Of 11 patients with grade 2 or higher flare in the glofitamab trial, 2 had analgesics alone, 6 had corticosteroids and analgesics, 1 had corticosteroids and anti-emetics and 2 needed no treatment (EU label). No label read gives a steroid drug or dose.","source":"smpc-columvi","quote":"Corticosteroids and analgesics should be considered to treat tumour flare."},{"action":"On glofitamab (US label), withhold the drug for grade 2 to 4 flare until the flare resolves","why":"The US label gives this rule in its dose-modification table without a stated reason; grade 1 flare is monitored without a hold. The EU glofitamab label has no hold rule for flare.","source":"label-glofitamab","quote":"Withhold COLUMVI until tumor flare resolves."},{"action":"On mosunetuzumab (EU label), temporarily withhold treatment for grade 3 or 4 tumour flare until symptoms have resolved","why":"The EU label names tumour flare among the grade 3 or 4 reactions that call for a pause. The US label has no row for flare; its general rule withholds for any other grade 3 or higher reaction until it is grade 1 or baseline.","source":"smpc-lunsumio","quote":"Patients who experience grade 3 or 4 reactions (e.g. serious infection, tumour flare, tumour lysis syndrome) should have treatment temporarily withheld until symptoms are resolved (see section 4.4)."},{"action":"On lenalidomide, grade 1 or 2 flare may be treated with NSAIDs, corticosteroids or opioid analgesics, and the drug may continue, at the doctor's discretion","why":"Both labels allow lenalidomide to continue without interruption or dose change through grade 1 or 2 flare. In the mantle cell lymphoma trial all reports were grade 1 or 2.","source":"label-lenalidomide","quote":"REVLIMID may be continued in patients with Grade 1 and 2 TFR without interruption or modification, at the physician's discretion."},{"action":"On lenalidomide, withhold the drug for grade 3 or 4 flare until it has settled to grade 1 or less","why":"Tumour flare reactions on lenalidomide have included fatal ones. The EU label adds NSAIDs, corticosteroids or narcotic analgesics during the hold, and a restart at the same dose level for the rest of the cycle.","source":"label-lenalidomide","quote":"In patients with Grade 3 or 4 TFR, it is recommended to withhold treatment with REVLIMID until TFR resolves to ≤ Grade 1."}],"bestInClass":{"statement":"There is no graded guideline on tumour flare that could be read; the best supported practice is what the labels share. Identify bulky disease and disease next to an airway or vital organ before the first dose and monitor those patients closely during initial treatment (US glofitamab and mosunetuzumab labels; the three EU labels ask for monitoring at critical anatomical sites; the US epcoritamab label is silent); tell patients the signs to report; consider corticosteroids and analgesics for symptoms; start standard treatment if compression or obstruction develops; and do not call early swelling progression on appearance alone (EU glofitamab label; LYRIC, for trials). The labels differ on whether to pause treatment, and each position is shown: the US glofitamab label withholds for grade 2 to 4 flare, the EU mosunetuzumab label for grade 3 or 4, the EU glofitamab label asks only for management as clinically indicated, and the epcoritamab trial allowed treatment to continue. For lenalidomide both labels allow treatment to continue through grade 1 or 2 flare at the doctor's discretion and withhold it for grade 3 or 4.","sources":["label-glofitamab","smpc-columvi","label-mosunetuzumab","smpc-lunsumio","smpc-tepkinly","label-epcoritamab","label-lenalidomide","smpc-revlimid","lyric-2016"]},"variants":[{"name":"Withhold the bispecific antibody, or continue through flare","differs":"The US glofitamab label withholds for grade 2 to 4 flare until it resolves and only monitors grade 1. The EU glofitamab label gives no hold rule for flare and says to manage as clinically indicated. The EU mosunetuzumab label withholds for grade 3 or 4 flare until symptoms resolve; the US mosunetuzumab label asks for monitoring and standard treatment of any compression and has no flare row in its dose table. The US epcoritamab label has no tumour flare warning; its trial description says continued treatment was permitted in suspected flare. The US mosunetuzumab and epcoritamab labels and the EU epcoritamab label each carry a general rule to withhold for other grade 3 or higher adverse reactions until grade 1 or baseline, which does not name flare.","evidence":"Label text from single-arm trials. In the glofitamab trial no patient stopped treatment because of flare and all but one event resolved (EU label).","sources":["label-glofitamab","smpc-columvi","label-epcoritamab","smpc-tepkinly","label-mosunetuzumab","smpc-lunsumio"]},{"name":"Antihistamine and corticosteroids, or corticosteroids and analgesics","differs":"For grade 2 to 4 flare the US glofitamab label names an antihistamine and corticosteroids. The EU label says corticosteroids and analgesics should be considered. A literature review, writing about flare on lenalidomide in chronic lymphocytic leukaemia, lists analgesics, NSAIDs, antihistamines and corticosteroids.","evidence":"Descriptive only. Of 11 patients with grade 2 or higher flare on glofitamab, 2 had analgesics alone, 6 had corticosteroids with analgesics including morphine derivatives, 1 had corticosteroids with anti-emetics and 2 needed no treatment (EU label).","sources":["label-glofitamab","smpc-columvi","taleb-2019"]},{"name":"Lenalidomide: restart rule after severe flare","differs":"The US label recommends withholding for grade 3 or 4 flare until it is grade 1 or less. The EU label adds NSAIDs, corticosteroids or narcotic analgesics during the hold and a restart at the same dose level for the rest of the cycle, and for grade 1 or 2 flare says the corticosteroids are of limited duration. The EU label also names who is at risk in mantle cell lymphoma: a high MIPI score at diagnosis or bulky disease, defined as a lesion of 7 cm or more.","evidence":"Label rules. Flare was reported in 13 of 134 patients (10%) in the mantle cell trial and 19 of 176 (10.8%) on lenalidomide with rituximab in AUGMENT; one case in a separate mantle cell trial was fatal (US label). The EU label gives 19 of 146 (13.0%) for its study NHL-007.","sources":["label-lenalidomide","smpc-revlimid"]},{"name":"Following the product labels and the 2024 consensus (Canadian guidance, funded by Roche)","differs":"A Canadian expert working group on bispecific antibodies for DLBCL, funded by Hoffmann-La Roche, gives no flare rules of its own and endorses the product monographs and the Crombie 2024 consensus for tumour flare.","evidence":"Expert opinion. The Crombie consensus itself could be read as an abstract only.","sources":["macdonald-2025","crombie-2024"]}],"grades":[{"claim":"Glofitamab: tumour flare in 12%, grade 3 in 2.8%, recurrent in two patients","grade":"Regulatory label; not graded","source":"label-glofitamab","quote":"Tumor flare was reported in 12% of patients who received COLUMVI, including Grade 2 tumor flare in 4.8% of patients and Grade 3 tumor flare in 2.8%."},{"claim":"Glofitamab, grade 2 to 4 flare: antihistamine and corticosteroids","grade":"Regulatory label; not graded","source":"label-glofitamab","quote":"Monitor for signs and symptoms of compression or obstruction due to mass effect secondary to tumor flare, and institute appropriate treatment including antihistamine and corticosteroids."},{"claim":"Glofitamab (EU): flare may mimic progression and is attributed to T cells entering the tumour","grade":"Regulatory label; not graded","source":"smpc-columvi","quote":"tumour flare is likely due to the influx of T cells into tumour sites following Columvi administration and may mimic progression of disease."},{"claim":"Mosunetuzumab: flare in 4%, with new or worsening pleural effusions, pain and swelling","grade":"Regulatory label; not graded","source":"label-mosunetuzumab","quote":"Among patients who received LUNSUMIO at the recommended dosage in the clinical trial, tumor flare occurred in 4%."},{"claim":"Mosunetuzumab (EU): flare in 3.1%, grade 3 in 1.4%","grade":"Regulatory label; not graded","source":"smpc-lunsumio","quote":"tumour flare (including pleural effusion and tumour inflammation) occurred in 3.1% (11/357) of patients, which included 1.4% grade 2 and 1.4% grade 3 events."},{"claim":"Mosunetuzumab (EU): monitor at critical anatomical sites","grade":"Regulatory label; not graded","source":"smpc-lunsumio","quote":"Lunsumio should be monitored and evaluated for tumour flare at critical anatomical sites."},{"claim":"Epcoritamab (EU): monitor at critical anatomical sites","grade":"Regulatory label; not graded","source":"smpc-tepkinly","quote":"epcoritamab should be monitored and evaluated for tumour flare at critical anatomical sites."},{"claim":"Epcoritamab (EU): flare in 1.6% on monotherapy, all grade 2","grade":"Regulatory label; not graded","source":"smpc-tepkinly","quote":"In study GCT3013-01, tumour flare occurred in 1.6% (6/382) of patients, all of which were grade 2."},{"claim":"Epcoritamab (US): treatment could continue in suspected flare in the trial","grade":"Regulatory label; not graded","source":"label-epcoritamab","quote":"In the setting of a suspected tumor flare reaction, continued treatment was permitted."},{"claim":"Lenalidomide: flare may mimic progression; monitoring recommended in mantle cell, follicular and marginal zone lymphoma","grade":"Regulatory label; not graded","source":"label-lenalidomide","quote":"Monitoring and evaluation for TFR is recommended in patients with MCL, FL, or MZL. Tumor flare reaction may mimic progression of disease (PD)."},{"claim":"Lenalidomide: symptom treatment for grade 1 and 2 flare","grade":"Regulatory label; not graded","source":"label-lenalidomide","quote":"Patients with Grade 1 and 2 TFR may also be treated with corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and/or narcotic analgesics for management of TFR symptoms."},{"claim":"Canadian guidance defers to the product monographs and the 2024 consensus for tumour flare","grade":"Expert working group, funded by Roche; not graded","source":"macdonald-2025","quote":"The EWG endorse recommendations from the respective product monographs and Crombie et al. (2024) for the management of non-CRS AEs"}],"sources":[{"key":"label-glofitamab","label":"Columvi (glofitamab) injection: US prescribing information, revised June 2026, sections 2.4, 5.4, 6.1 and 17","publisher":"Genentech, a member of the Roche Group (DailyMed, US National Library of Medicine)","year":2026,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3516e753-f064-4d30-9bd5-e3f2e143f75d","gradingScheme":"Regulatory label; not graded.","read":"full-text","accessed":"2026-11-17"},{"key":"smpc-columvi","label":"Columvi (glofitamab): EU product information, summary of product characteristics sections 4.4 and 4.8 and package leaflet (first authorised 2023; the PDF prints no revision date)","publisher":"European Medicines Agency (marketing authorisation holder Roche Registration GmbH)","year":2023,"url":"https://www.ema.europa.eu/en/documents/product-information/columvi-epar-product-information_en.pdf","gradingScheme":"Regulatory label; not graded.","read":"full-text","accessed":"2026-11-17"},{"key":"label-mosunetuzumab","label":"Lunsumio (mosunetuzumab) injection: US prescribing information, revised June 2026, sections 2.4 and 5.6","publisher":"Genentech, a member of the Roche Group (DailyMed, US National Library of Medicine)","year":2026,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2ef0cf38-101c-4681-98fe-c05dc9ead443","gradingScheme":"Regulatory label; not graded.","read":"full-text","accessed":"2026-11-17"},{"key":"smpc-lunsumio","label":"Lunsumio (mosunetuzumab): EU product information, summary of product characteristics sections 4.2, 4.4 and 4.8 (first authorised 2022; the PDF prints no revision date)","publisher":"European Medicines Agency (marketing authorisation holder Roche Registration GmbH)","year":2022,"url":"https://www.ema.europa.eu/en/documents/product-information/lunsumio-epar-product-information_en.pdf","gradingScheme":"Regulatory label; not graded.","read":"full-text","accessed":"2026-11-17"},{"key":"label-epcoritamab","label":"Epkinly (epcoritamab) injection: US prescribing information, revised June 2026, sections 2.6, 6.1 and 14","publisher":"Genmab US (DailyMed, US National Library of Medicine)","year":2026,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d7836711-b677-412d-bf2d-0f7c8444103a","gradingScheme":"Regulatory label; not graded.","read":"full-text","accessed":"2026-11-17"},{"key":"smpc-tepkinly","label":"Tepkinly (epcoritamab): EU product information, summary of product characteristics sections 4.2, 4.4 and 4.8 (first authorised 2023; the PDF prints no revision date)","publisher":"European Medicines Agency (marketing authorisation holder AbbVie Deutschland GmbH & Co. KG)","year":2023,"url":"https://www.ema.europa.eu/en/documents/product-information/tepkinly-epar-product-information_en.pdf","gradingScheme":"Regulatory label; not graded.","read":"full-text","accessed":"2026-11-17"},{"key":"label-lenalidomide","label":"Revlimid (lenalidomide) capsules: US prescribing information, revised March 2023, sections 5.5 and 5.11","publisher":"Celgene, a Bristol Myers Squibb company (DailyMed, US National Library of Medicine)","year":2023,"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5fa97bf5-28a2-48f1-8955-f56012d296be","gradingScheme":"Regulatory label; not graded.","read":"full-text","accessed":"2026-11-17"},{"key":"smpc-revlimid","label":"Revlimid (lenalidomide): EU product information, summary of product characteristics sections 4.2, 4.4 and 4.8 (first authorised 2007; the PDF prints no revision date)","publisher":"European Medicines Agency (marketing authorisation holder Bristol-Myers Squibb Pharma EEIG)","year":2007,"url":"https://www.ema.europa.eu/en/documents/product-information/revlimid-epar-product-information_en.pdf","gradingScheme":"Regulatory label; not graded.","read":"full-text","accessed":"2026-11-17"},{"key":"lyric-2016","label":"Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy (LYRIC)","publisher":"Blood (Cheson et al.)","year":2016,"url":"https://doi.org/10.1182/blood-2016-05-718528","doi":"10.1182/blood-2016-05-718528","gradingScheme":"Workshop consensus; provisional recommendations, not graded.","read":"abstract","accessed":"2026-11-17"},{"key":"britto-2025","label":"Bispecific antibody toxicities","publisher":"CMAJ (Britto et al.; three authors declare research funding or honoraria from drug companies)","year":2025,"url":"https://doi.org/10.1503/cmaj.241384","doi":"10.1503/cmaj.241384","gradingScheme":"Practice summary; not graded.","read":"full-text","accessed":"2026-11-17"},{"key":"taleb-2019","label":"Tumour flare reaction in cancer treatments: a comprehensive literature review","publisher":"Anti-Cancer Drugs (Taleb)","year":2019,"url":"https://doi.org/10.1097/CAD.0000000000000814","doi":"10.1097/CAD.0000000000000814","gradingScheme":"Literature review; not graded.","read":"full-text","accessed":"2026-11-17"},{"key":"macdonald-2025","label":"Practical guidance for the expanded implementation and provision of bispecific antibodies for diffuse large B-cell lymphoma (DLBCL) across Canada (funded by Hoffmann-La Roche)","publisher":"Current Oncology (MacDonald et al.; research and publication charge funded by Hoffmann-La Roche Ltd)","year":2025,"url":"https://doi.org/10.3390/curroncol32080460","doi":"10.3390/curroncol32080460","gradingScheme":"Expert working group consensus; not graded.","read":"full-text","accessed":"2026-11-17"},{"key":"crombie-2024","label":"Consensus recommendations on the management of toxicity associated with CD3xCD20 bispecific antibody therapy","publisher":"Blood (Crombie et al.)","year":2024,"url":"https://doi.org/10.1182/blood.2023022432","doi":"10.1182/blood.2023022432","read":"abstract","accessed":"2026-11-17"}],"upgrades":[],"gaps":["No graded guideline on tumour flare could be read, and no source read reports a trial comparing ways of managing it. Every management step here is label text or a short practice summary.","Crombie et al., Blood 2024, the consensus recommendations on CD3xCD20 bispecific antibody toxicity, could be read as an abstract only: ashpublications.org returned 403 to a script on 16 November 2026, the paper is not in PubMed Central, and on 17 November 2026 Europe PMC listed no open copy. The abstract does not mention tumour flare, so what the consensus recommends for it is not reported here, and its funding statement could not be checked.","The LYRIC criteria (Cheson et al., Blood 2016) were read as an abstract only. The abstract gives the 'indeterminate response' idea; the size and timing thresholds that define its categories are in the full paper and are not given here. The abstract discusses checkpoint inhibitors and recommendations for clinical trials; it does not name bispecific antibodies. On 17 November 2026 the author copy listed in the King's College London repository returned 403 for the PDF, so the full paper is still unread.","The labels differ on pausing a bispecific antibody for flare (the US glofitamab label withholds for grade 2 to 4 and the EU mosunetuzumab label for grade 3 or 4; the EU glofitamab label and the epcoritamab trial do not require it), and no source read explains or resolves the difference.","No source read gives a steroid drug, dose or duration for tumour flare, or says when to image, drain an effusion, or admit.","No source read gives a bedside rule for telling flare from cytokine release syndrome. The CMAJ summary says only that the features overlap and treatment should be given at the same time.","The US epcoritamab label has no tumour flare warning section and no advice on monitoring for it; its EU label has one. Odronextamab has a record here but its label was not read, so it is not included.","The US bispecific labels say adverse reactions were graded by the NCI Common Terminology Criteria for Adverse Events (version 4.03 for glofitamab, 4.0 for mosunetuzumab, 5.0 for epcoritamab), but no label read prints what grade 1 to 4 tumour flare means.","The patient advice to report symptoms straight away rests on the EU package leaflets for glofitamab and mosunetuzumab, which list tumour flare among serious side effects to tell the doctor about straight away. The US medication guides say to tell the healthcare provider and give no time limit. No source read says when to ring an emergency number.","No glossary term for tumour flare or pseudo-progression exists in the corpus to link."]},"route":"/protocols/tumour-flare-on-bispecific-antibodies-and-immunomodulatory-drugs/","neighbours":{"protocol":[{"id":"crs-grading-and-management","kind":"protocol","name":"Cytokine release syndrome after CAR T-cell therapy: ASTCT grading, tocilizumab and steroids","route":"/protocols/crs-grading-and-management/"},{"id":"svc-obstruction","kind":"protocol","name":"Superior vena cava obstruction in cancer: recognition, imaging, stenting and treatment of the cause","route":"/protocols/svc-obstruction/"},{"id":"bispecific-step-up-dosing","kind":"protocol","name":"T-cell engaging bispecific antibodies: step-up dosing, monitoring and outpatient delivery","route":"/protocols/bispecific-step-up-dosing/"},{"id":"tumour-lysis-syndrome-prevention-and-treatment","kind":"protocol","name":"Tumour lysis syndrome: risk assessment, prophylaxis and treatment","route":"/protocols/tumour-lysis-syndrome-prevention-and-treatment/"}],"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"},{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/"},{"id":"marginal-zone-lymphoma","kind":"cancer","name":"Marginal zone lymphoma","route":"/cancers/marginal-zone-lymphoma/"}],"drug":[{"id":"epcoritamab","kind":"drug","name":"Epcoritamab","route":"/drugs/epcoritamab/"},{"id":"glofitamab","kind":"drug","name":"Glofitamab","route":"/drugs/glofitamab/"},{"id":"lenalidomide","kind":"drug","name":"Lenalidomide","route":"/drugs/lenalidomide/"},{"id":"mosunetuzumab","kind":"drug","name":"Mosunetuzumab","route":"/drugs/mosunetuzumab/"}],"term":[{"id":"crs","kind":"term","name":"Cytokine release syndrome (CRS)","route":"/terms/crs/"},{"id":"imid","kind":"term","name":"Immunomodulatory drugs (IMiDs) and CELMoDs","route":"/terms/imid/"},{"id":"lugano-classification","kind":"term","name":"Lugano classification / Ann Arbor staging","route":"/terms/lugano-classification/"},{"id":"tumor-lysis-syndrome","kind":"term","name":"Tumour lysis syndrome (TLS)","route":"/terms/tumor-lysis-syndrome/"}]}}